Enveric - התחייבויות לטווח ארוך של החברה ENVB

Enveric Biosciences (ENVB) is implementing energy-efficient methods within its cannabinoid drug development centers while strictly adhering to environmental regulations. This chart of long-term liability costs, which currently stands at 0.00, complements data regarding the scalable AI platform Psybrary for creating psilocybin-based molecules for subsequent licensing. Simultaneously, the company is fighting for patent protection of new psychedelics to limit the influence of pharmaceutical behemoths.

Long-term liabilities record the total volume of borrowed funds with a maturity of more than one year. For Enveric Biosciences (ENVB), the amount of the organization's long-term financial debt reflects the cost of resources required to develop drugs for pain and anxiety. An increase in the credit load may indicate a capital deficit during the conduct of clinical trials. Conversely, a reduction in debt demonstrates financial stability. It is important for the investor to correlate this indicator with the pace of patent acquisition and the search for strategic partners.